Palmitoyl tetrapeptide-7 is a cosmetic ingredient made of palmitic acid joined to the four-amino-acid peptide GQPR. It is one of the two peptides in the trade-name blend Matrixyl 3000. This guide covers its structure, research and safety review. Sources were checked on November 17, 2026.
Quick answer: Palmitoyl tetrapeptide-7 is Pal-Gly-Gln-Pro-Arg, a fatty-acid-linked tetrapeptide. It is paired with palmitoyl tripeptide-1 in Matrixyl 3000 and is contained in the trade-name mixture Rigin. CosIng lists it as a skin conditioning ingredient. Human data come mostly from studies of blends, so its own effect is hard to separate.
Vitrapep does not sell palmitoyl tetrapeptide-7; this page is a reference summary of published research and regulatory information.
What is palmitoyl tetrapeptide-7?
Palmitoyl tetrapeptide-7 is a lipopeptide, meaning a peptide joined to a fatty acid. CosIng defines it as “the reaction product of palmitic acid and Tetrapeptide-7” (CosIng, 2026). The peptide is glycine, glutamine, proline and arginine, written GQPR. PubChem lists the formula C34H62N8O7 and a molecular weight of 694.9 g/mol (PubChem CID 10078408). Our guide to types of peptides covers how such chains are classed.
CIR describes the GQPR portion as “a natural fragment of the IgG immunoglobulins” (CIR, 2014). An earlier CIR draft noted that the ingredient dictionary listed palmitoyl tetrapeptide-3 as a technical name for palmitoyl tetrapeptide-7 (CIR draft, 2012). PubChem keeps both names as synonyms, along with “N-Palmitoylrigin.”
Two trade names matter. CIR describes Rigin as a trade-name mixture containing palmitoyl tetrapeptide-7. Croda’s product page lists palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 in the INCI listing for Matrixyl 3000 (Croda, 2026). The partner peptide has its own guide: palmitoyl tripeptide-1.
Palmitoyl tetrapeptide-7: key facts
| Fact | Detail |
|---|---|
| INCI name | Palmitoyl Tetrapeptide-7 (older technical name: palmitoyl tetrapeptide-3) |
| Structure type | Lipopeptide: palmitoyl group on a linear four-amino-acid peptide |
| Sequence | Pal-Gly-Gln-Pro-Arg (Pal-GQPR) |
| Molecular formula | C34H62N8O7 |
| Molecular weight | 694.9 g/mol |
| Main cosmetic function (CosIng) | Skin conditioning (miscellaneous) |
| Trade name(s) | Rigin; one of two peptides in Matrixyl 3000 |
How does palmitoyl tetrapeptide-7 work?
The proposed mechanism rests on inflammation signaling, but the public evidence is thin. A 2012 CIR draft summarized reports that palmitoyl tetrapeptide-7 lowered interleukin-6 (IL-6) secretion by cultured keratinocytes. This held in resting cells and after UVB exposure, with a smaller effect in fibroblasts. CIR added that “details relating to the test protocol and study results were not included” (CIR draft, 2012).
The palmitoyl tail adds fat solubility. A 2026 study with three female volunteers tested a serum containing Matrixyl 3000. OrbiSIMS mass spectrometry detected both peptides in every stratum corneum layer, with signal falling with depth. The authors suggested the peptides sat on the outer surfaces of skin cells rather than inside them (Trzaska et al., 2026). Two authors worked for a cosmetics company.
What is palmitoyl tetrapeptide-7 used for?
CosIng lists one function: “skin conditioning - miscellaneous.” CIR says the ingredients in its group function primarily as skin conditioning agents. Data from FDA’s Voluntary Cosmetic Registration Program, cited by CIR, showed 249 reported uses of palmitoyl tetrapeptide-7. Nearly all were leave-on products. Of those, 102 were eye-area products (CIR, 2014).
Under US law, intended use decides whether a product is a cosmetic or a drug. Claims to affect the structure or function of the body can make a product a drug (FDA, 2024).
What does the research show?
Almost every human study tested palmitoyl tetrapeptide-7 inside a blend. We found no peer-reviewed, placebo-controlled trial of it alone.
Matrixyl 3000 half-face study. CIR summarized a Sederma study in 24 volunteers with a mean age of 56.1 years. Matrixyl 3000 cream was compared with a plain cream on opposite halves of the face. At day 56, deep wrinkles and roughness had fallen versus day 0, and elasticity and tone had risen. The plain cream showed no significant change (CIR, 2014). The source is a manufacturer synopsis, not a peer-reviewed paper.
Skin imaging study. Sederma and university scientists tested a blend of palmitoyl oligopeptide and palmitoyl tetrapeptide-7. Ultrasound showed a thinner, denser low-echo band under the epidermis, and confocal microscopy showed better matrix structure than placebo. The abstract does not give subject numbers (Mondon et al., 2015).
Eye cream trial. A company-led study tested an eye cream with both palmitoyl peptides, a fermentation filtrate and N-acetylneuraminic acid. At week 12, the authors reported gains of 28.12% in hydration, 18.81% in elasticity and 54.99% in ultrasound collagen measures (Yang et al., 2024). The abstract does not state the number of participants.
What safety data exist?
The CIR Expert Panel reviewed palmitoyl tetrapeptide-7 with tripeptide-1, hexapeptide-12 and related ingredients. Its final report of June 30, 2014, found them “safe in the present practices of use and concentration in cosmetics.” The conclusion covers only the GQPR, GHK and VGVAPG sequences (CIR, 2014). It was later published in a journal (Johnson et al., 2018). Data specific to palmitoyl tetrapeptide-7 include:
- Rigin showed no potential for irritation or allergic sensitization in a repeated insult patch test on 52 men and women aged 18 to 79.
- Rigin was not mutagenic in an Ames bacterial test, with or without metabolic activation.
- In an egg-membrane test of eye irritation potential, Rigin was slightly irritating.
- Use-concentration data for palmitoyl tetrapeptide-7 were not included in the industry survey.
CIR found no published carcinogenicity or reproductive toxicity data for the group. CosIng lists no EU restrictions and no SCCS opinion for this ingredient.
What is palmitoyl tetrapeptide-7’s regulatory status, and how is it used in research?
In the United States, cosmetic products and ingredients, other than color additives, need no FDA approval before sale (FDA, 2025). Palmitoyl tetrapeptide-7 is a cosmetic ingredient, not an FDA-approved drug.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) became law on December 29, 2022. It added facility registration, product listing, serious adverse event reporting, safety substantiation records and mandatory recalls (FDA Voices, 2026). In the EU, CosIng lists the ingredient under CAS 221227-05-0 with an active status.
In research, Matrixyl 3000 has served as a test material for skin-penetration imaging, as in the Nottingham OrbiSIMS work above. For the wider class, see peptides in skincare.
Frequently asked questions about palmitoyl tetrapeptide-7
Is palmitoyl tetrapeptide-7 the same as Matrixyl 3000?
No. Matrixyl 3000 is a blend whose INCI listing includes palmitoyl tetrapeptide-7 and palmitoyl tripeptide-1.
Is palmitoyl tetrapeptide-3 a different ingredient?
A 2012 CIR draft noted that the dictionary listed palmitoyl tetrapeptide-3 as a technical name for palmitoyl tetrapeptide-7. PubChem lists both names for the same structure.
What is Rigin?
CIR describes Rigin as a trade-name mixture that contains palmitoyl tetrapeptide-7.
Is palmitoyl tetrapeptide-7 approved by the FDA?
No. FDA does not approve cosmetic ingredients, other than color additives, before they go on the market.
How does it differ from Matrixyl?
Matrixyl is palmitoyl pentapeptide-4, a different peptide. Our Matrixyl guide compares the Matrixyl names.
What to know now
- Structure: palmitic acid on GQPR; C34H62N8O7; 694.9 g/mol.
- Origin: GQPR is a natural fragment of immunoglobulin G, per CIR.
- Trade names: Rigin; one half of Matrixyl 3000.
- Evidence: human data come from blends; IL-6 claims lack published protocols.
- Safety: CIR found it safe as used in 2014; patch test on 52 people was negative.
- Status: a cosmetic ingredient, not an FDA-approved drug.
What we’re watching
FDA rules under MoCRA. The MoCRA page, updated October 29, 2026, lists good manufacturing practice and fragrance allergen labeling rules that the law requires (FDA, 2026). Related guides: palmitoyl hexapeptide-12 and palmitoyl tripeptide-38.